Answers are grounded in this paper and cite their sources.
In type 2 inflammation associated diseases, systemic corticosteroid use remains common despite the introduction of corticosteroid-sparing treatments. Timely referrals to specialist assessment could reduce the overall systemic corticosteroid exposure.
No takes yet. Share an insight, caveat, or question.
Håkansson et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: